Raltegravir for the prevention of mother-to-child transmission of HIV MJ Trahan, V Lamarre, ME Metras, N Lapointe, F Kakkar Centre Hospitalier Universitaire.

Slides:



Advertisements
Similar presentations
Principles of care of the HIV-1 infected pregnant mother Protection of mothers from mono- and dual- therapies likely to induce resistance: Women refusing.
Advertisements

Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
P1060 commentary Philippa Musoke MBChB Makerere University –Johns Hopkins University Research Collaboration, Kampala Uganda.
Accomplishments Year 1 Encouraged HIV testing counseling with referrals to Phidisa 1 Education of Nursing Staff on Pediatric Wards Lectures to Medical.
Thailand New National Guideline for PMTCT 2010 Suchat Hongsiriwon, MD Department of Pediatrics Chonburi Hospital.
Perinatal HIV Case Series Reports for Births in Presenter: Elvia Ledezma Texas Department of State Health Services.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Foundation J2J Global Media Training on HIV/AIDS July 14, 2010 Vienna, Austria.
THE CORE STUDY COMPARING TWO STRATEGIES FOR ENROLLING HIV-INFECTED PREGNANT WOMEN FROM ANTENATAL CARE TO CARE AND TREATMENT SERVICES IN CAMEROON: CONTINUUM.
“Getting to Zero: Thailand’s Experience with E-MTCT” Petchsri Sirinirund Advisor on HIV/AIDS Policy and Programme Department of Disease Control, Thailand.
PMTCT of HIV- Dr Abhimanyu Makane MBBS CHIV FHM(CMC,Vellore) AAHIVS Consultant HIV Physician Sterling Multispecialty Hospial,Nigdi,Pune.
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Pediatric ID Previous presentation by Susan Schuval, MD
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2009* * Numbers are based on reports received rather than children seen to.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
1 Advantages and risks for a child to be exposed to the triple prophylaxis during pregnancy and breastfeeding What is the best for the child ? Pr C. Courpotin.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
PMTCT: a moving target or a moving strategy? 23rd June 2008 MSF Access Campaign.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
CARE OF THE NEONATE. August Infants Born to Mothers with Unknown HIV Infection Status (1) Determine possible HIV exposure and need.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
8èmes Rencontres Nord-Sud Avelin Aghokeng IRD-UMI233 & University of Montpellier I Yaoundé-Cameroon Avelin Aghokeng IRD-UMI233 & University of Montpellier.
The Pregnancy Journey Open discussion. HIV and AIDS 2013 Romania Cumulative number people diagnosed with HIV since ,261 (of which 9,946 diagnosed.
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.
HIV DISEASE IN PREGNANCY
02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:
SPECIAL CONSIDERATIONS August
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
Transmission of HIV from mother to fetus. - is not simply one of the major health problems today, but also a big problem in the field of human rights.
Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.
Atazanavir Use in Pregnancy : a report of 33 cases St George’s Hospital South West London HIV & GUM Clinical Services Network Macky Natha 1, Phillip Hay.
The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
HIV Prevention in Mothers and Infants DR KANUPRIYA CHATURVEDI.
Neonatal ART regimens James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children’s Hospital & University of Cape Town Right to.
A Call to Action Children – The missing face of AIDS.
MATERNAL ANTIRETROVIRAL THERAPY AND INFANT OUTCOMES THROUGHOUT THE FIRST YEAR OF LIFE: results from the DREAM study in Dschang, Cameroon Taafo F, Doro.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Understanding the Rationale of the 2015 WHO Guidelines on PrEP IAS Satellite Session Heather Watts M.D. Office of the Global AIDS Coordinator July 18,
HIV Point of Care tests in Babies Study (BABY) Operational evaluation of HIV Point of Care tests for very early infant HIV diagnostics in infants born.
RALTEGRAVIR vs LPV/R FOR LATE-PRESENTERS PREGNANT WOMEN.
OVERVIEW OF PREVENTING MOTHER TO CHILD TRANSMISSION OF HIV
Module 4 (e) Pregnancy and Breast Feeding
Birth Weight and Preterm Delivery Outcomes of Perinatally vs
The Effect of Family Social Intervention on Treatment Response in Children with HIV Infection Francine Cheng DO, Janak Patel MD, Debbie Konopik SWA, and.
What’s New in the Perinatal Guidelines
Antiretrovirals during pregnancy
The use of cotrimoxazole prophylaxis in the context of HIV infection
Cepheid Symposium, IAS 23rd July 2018
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
Adele Schwartz Benzaken
Switch to RAL-containing regimen
Switch to RAL-containing regimen
Presentation transcript:

Raltegravir for the prevention of mother-to-child transmission of HIV MJ Trahan, V Lamarre, ME Metras, N Lapointe, F Kakkar Centre Hospitalier Universitaire Sainte Justine, Université de Montréal Centre Maternel et Infantile sur le Sida

No conflicts of interest to declare

Prevention of mother-child transmission (PMTCT): Canadian Context  Through the success of the national PMTCT programs, the overall risk of perinatal HIV transmission in the developed world has decreased to <1%  However, mother-to-child transmission has not been eliminated in Canada  Canadian Perinatal HIV surveillance database ( ) ( Poster MOPEC445, Bitnun et al): 3200 pregnancies  0.1% > 4 weeks cART during pregnancy  3.1% detectable VL ( c/ml ) at time of delivery  4.3% ≤ 4 weeks of cART during pregnancy  15% without any maternal treatment  New strategies needed for the management of these high-risk situations Late presenting mothers Treatment failure during pregnancy Infants at “high-risk” of HIV infection

Use of RAL for PMTCT in high-risk situations  Raltegravir: FDA Pregnancy Category C, due to limited data to support its use  Under select circumstances, RAL has been used in late pregnancy in women with high viral loads to rapidly decrease viral load prior to delivery = case series on the use of RAL during pregnancy  Evidence of transplacental transfer of RAL (IMPAACT 1026S, 1097), however limited data on long term outcomes of infants exposed in utero to RAL  Toxicity concerns:  Animal studies: Supernumerary ribs in rabbits exposed to 3 fold human dose  Theoretical: Possible increase in unconjugated bilirubin, increasing risk of kernicterus (RAL and bilirubin are both albumin bound, and metabolized by UGTA1)

Objectives 1.To determine clinical outcomes among newborns exposed to RAL in utero (Maternal PMTCT) 2. To describe the use of RAL for the prophylaxis of newborns at high risk of HIV acquisition (Neonatal PMTCT)

Methods  Retrospective study from the Centre Maternel et Infantil sur le SIDA (CMIS) mother-child cohort, CHU Sainte-Justine, Montréal, Quebec  All infants born to women treated with RAL during pregnancy in the CMIS mother-child cohort between 2010 and 2015 (n=18)  Neonatal outcomes:  Clinical outcomes, biochemistry, growth to 6 months of age  Comparison group of infants exposed to combination ART with Atazanvir/Ritonavir or Lopinavir/Ritonavir in utero, matched by nearest date of birth

Use of RAL during pregnancy  RAL given to mothers at standard dosing of 400 mg BID during pregnancy in addition to cART (PI based) (n=18)  GA at beginning of maternal ARV treatment:  Pre-pregnancy (5)  During pregnancy (13): mean GA= 31.9 weeks (range weeks)  Indications for RAL:  Drug Resistance (6)  High VL (>1000 copies/ml) in third trimester despite treatment (7)  Late initiation of therapy (7) (mean GA at start): 30.4 wks  Maternal characteristics at delivery:  CD4 count (mean): 370 cells/mm 3 ( )  Viral load  Undetectable (14)  Detectable (4) (40, 248, 910, copies/ml)

Clinical outcomes among RAL exposed infants

Biochemistry

Congenital Anomalies

Growth parameters to 6 months of age

Newborns Exposed In Utero – RAL Levels PatientRAL level (mg/L)Age of first RAL level(days) 1< 0.01 (undetectable) (16 hours of life) 3Not available- 4< 0.01 (undetectable) (30 hours of life) 7Not available- 8< 0.01 (undetectable)14 9< 0.01 (undetectable)14 Therapeutic RAL dosage: 0.02 mg/L Clarke et al (MPACT P1097), JAIDS 2014

Summary – use of RAL in Pregnancy  No significant adverse events related in utero RAL exposure to 6 months of follow-up when compared to infants exposed to KAL or ATZ based maternal drug regimens alone  No HIV transmission among the “high-risk” group infants of RAL treated mothers, vs. 4.3 – 8.8% among similar cohort of high-risk HIV exposed infants of late presenting mothers (CPHSP 2014, Bitnun, CID 2014 ))

Neonatal Prophylaxis of Infants Born to Multidrug-Resistant Mothers  New challenge – Pregnancy among perinataly-infected women  Lifetime of ARV exposure + difficulties with adherence = multidrug- resistance  Challenge for post-natal prophylaxis since mothers are resistant to standard drugs approved for use in neonates (ZDV/3TC/NVP)  Formulation (granules for suspension) attractive option for prophylaxis of newborns at high risk of HIV infection  Clinical trial underway (IMPAACT P1110) for infants <4 weeks of age  RAL was used for neonatal prophylaxis as part of a triple-drug regimen in two newborns at high risk of HIV-infection in the CMIS cohort (Merck, Special Access, Health Canada Compassionate use)

Newborn 1 Indication for RAL: Detectable maternal VL in 3 rd trimester (480 copies/ml), history of non-adherence, and multidrug resistance (NNRTI, NRTI and PIs) Maternal Regimen: Dolutegravir, Etravirine, Darunavir/Ritonavir, TDF/FTC Infant Regimen: AZT 4mg/kg/ BID, 3TC 2mg/kg/BID, RAL 1.5mg/kg/BID for 6 weeks

Newborn 2 Indication for RAL: Maternal refusal of ART during pregnancy, VL copies/ml at delivery, history of non-adherence during adolescence and multi-drug resistant (NRTI,NNRTI) Infant Regimen: AZT 4mg/kg/ BID, 3TC 2mg/kg/BID, Lopinavir/Ritonavir 300mg/m 2 BID, RAL 1.5mg/kg/BID for 6 weeks

Outcomes  Variability in drug levels between the two infants requiring TDM and dose adjustment  No adverse effects through 6 weeks of therapy (weekly haematology, biochemistry)  Both infants confirmed HIV uninfected (HIV viral load negative at birth, 2 weeks, 2 month, 4 months and HIV DNA PCR negative 4 weeks)  RAL well tolerated, minimal preparation challenges

Summary: RAL for PMTCT  Raltegravir in pregnancy may have a role to play in prevention of mother- child-transmission in high-risk situations  No cases of transmission among high-risk RAL exposed newborns  No significant adverse events from in utero exposure, to 6 months of follow-up  RAL granules for suspension in the newborn at doses of mg/kg BID was well tolerated with no adverse events:  Further dosing recommendations: IMPAACT P1110, Poster MOPEB196  However – if this strategy is to be used, until further PK and toxicity data becomes available  Careful monitoring during pregnancy  Therapeutic drug monitoring during treatment of newborns  Long -term follow-up of exposed infants is necessary

Acknowledgements Merck Product Development Dr Hedy Teppler Dr Jeff Fortin Dr. Nancy Sheehan